News
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
Viridian Therapeutics reveals promising long-term results for veligrotug in treating thyroid eye disease, highlighting its ...
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
A recent study reveals a significant rise in childhood astigmatism linked to the COVID-19 pandemic, independent of myopia.
At ARVO 2025, in Salt Lake City, Utah, Roger Goldberg, MD, MBA, talked about his presentation on the effect of AREDS vitamins in geographic atrophy.
At ARVO 2025, in Salt Lake City, Utah, Viha Vig, talked about her poster presentation investigating the relationship between ocular and systemic mitochondrial diseases and dementia ...
Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer’s Disease and ...
Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal ...
A machine learning model incorporating treated astigmatism and nuanced inputs is advancing the precision and personalization ...
Rishi Singh, MD, discusses faricimab's real-world effectiveness in treating diabetic macular edema, highlighting improved ...
Shifting from a regulatory role to driving innovation directly, Eydelman discusses how the Collaborative Community on ...
SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results